Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
Plus
17
Ṁ6697resolved Jan 2
Resolved
NO1D
1W
1M
ALL
GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment. This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Sort by:
made a market that breaks this out by end year and added a M5k subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl
Related questions
Related questions
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
26% chance
Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
41% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
80% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will AOH1996 be FDA approved before 2040?
44% chance
Will an oral insulin pill be publicly available before the end of 2025?
24% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
42% chance